Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)

CONCLUSION: Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.PMID:36609911 | DOI:10.1007/s12282-022-01425-2

Source: Breast Cancer - January 7, 2023 Category: Cancer & Oncology Authors: Manabu Futamura Kazuhiro Ishihara Yasuko Nagao Atsuko Ogiso Yoshimi Niwa Takumi Nakada Yoshihiro Kawaguchi Ai Ikawa Iwao Kumazawa Ryutaro Mori Mai Kitazawa Yoshiki Hosono Masashi Kuno Mana Kawajiri Akira Nakakami Makoto Takeuchi Akemi Morikawa Yoshihisa T Source Type: research